Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Sarepta Therapeutics (SRPT – Research Report) and Emergent Biosolutions (EBS – Research Report).
Sarepta Therapeutics (SRPT)
TD Cowen analyst Ritu Baral maintained a Buy rating on Sarepta Therapeutics today and set a price target of $135.00. The company’s shares closed last Thursday at $115.89.
According to TipRanks.com, Baral is a 5-star analyst with an average return of
Currently, the analyst consensus on Sarepta Therapeutics is a Strong Buy with an average price target of $125.27, representing a 5.0% upside. In a report issued on December 29, WBB Securities also maintained a Buy rating on the stock with a $185.00 price target.
See today’s best-performing stocks on TipRanks >>
Emergent Biosolutions (EBS)
According to TipRanks.com, Peaker is a 5-star analyst with an average return of
Emergent Biosolutions has an analyst consensus of Moderate Sell, with a price target consensus of $5.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on SRPT:
- Sarepta reports preliminary FY23 net product revenue $1.145B
- Regenxbio: Sarepta granted summary judgment on invalidity in patent suit
- Arcellx named as 2024 Top Pick, added to Conviction List at Needham
- Sarepta submits efficacy supplement to expand Elevidys label
- Sarepta price target lowered to $130 from $160 at Mizuho
